US Patent No: 7,582,636

Number of patents in Portfolio can not be more than 2000

Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor

Stats

ALSO PUBLISHED AS: 20060270848
ATTORNEY / AGENT: (SPONSORED)
 

Importance

Loading Importance Indicators... loading....

Abstract

The present invention relates to Gonadotropin Releasing Hormone (GnRH, also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.

Loading the Abstract Image... loading....

First Claim

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
WYETHMADISON, NJ2039

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Lundquist,, IV Joseph T - 1 0
Pelletier, Jeffrey C Lafayette Hill, PA 14 94
Vera, Matthew D - 2 0

Cited Art

Patent Info (Count) # Cites Year
 
WYETH (12)
6,313,126 Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression 12 1999
6,310,066 Antipsychotic indolyl derivatives 10 2000
6,306,859 N-substituted imide derivatives with serotonergic activity 9 2000
2005/0282,820 Processes for preparing gonadotropin releasing hormone receptor antagonists 7 2005
2006/0019,965 Gonadotropin releasing hormone receptor antagonists 8 2005
2006/0111,355 Gonadotropin releasing hormone receptor antagonists 10 2005
2006/0189,616 7-Substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor 8 2006
2006/0189,617 Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor 9 2006
2006/0189,618 4-Substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor 7 2006
2006/0189,619 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)p-yrido[2,3-b]]pyrazi ne compounds 7 2006
2006/0264,631 Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor 7 2006
2006/0270,848 Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of gonadotropin releasing hormone receptor 7 2006
 
TAKEDA PHARMACEUTICAL COMPANY LIMITED (4)
2004/0102,502 Preventing/remedies for portal hypertension 7 2003
2004/0121,008 Process for producing sustained release preparation 10 2003
2004/0219,208 Sustained-release medicines 15 2004
2005/0101,647 Bicyclic derivative, its production and use 10 2004
 
DUPHAR INTERNATIONAL RESEARCH B.V. (2)
4,833,142 Blood-pressure lowering 4-bicyclic-1-piperazinyl-alkyl amides 17 1987
5,424,313 Bibyclic heteroacrylpiperazine derivatives having psychotropic activity, and pharmaceutical compositions containing these derivatives 24 1993
 
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2)
5,576,460 Preparation of arylamines 55 1994
6,307,087 Ligands for metals and improved metal-catalyzed processes based thereon 45 1999
 
SCIOS INC. (2)
6,476,031 Quinazoline derivatives as medicaments 46 1999
6,277,989 Quinazoline derivatives as medicaments 107 2000
 
ABBVIE INC. (1)
2001/0020,030 Cell adhesion-inhibiting antiinflammatory compounds 28 2001
 
ABX (1)
2002/0182,623 Reagent and process for the identification and counting of biological cells 18 2002
 
AIR PRODUCTS AND CHEMICALS, INC. (1)
6,492,517 Method for preparing halomethyl heterocyclic compounds 9 2001
 
AMERICAN HOME PRODUCTS CORPORATION (1)
2002/0013,324 N-substituted imide derivatives with serotonergic activity 9 2001
 
AVENTIS PHARMA S.A. (1)
2005/0009,894 Benzimidazole derivatives and their use as KDR kinase protein inhibitors 14 2004
 
BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (1)
2004/0082,798 Novel amino dicarboxylic acid derivatives with pharmaceutical properties 29 2003
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (1)
5,643,944 Ovulation control by regulating nitric oxide levels 8 1995
 
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (1)
6,821,967 Substituted piperazine derivatives, the preparation thereof and their use as medicaments 8 2002
 
DAIICH PHARMACEUTICAL, CO., LTD. (1)
6,399,629 Efflux pump inhibitors 32 1998
 
DELALANDE S.A. (1)
4,459,296 Piperazines and homopiperazines, N-substituted by an aromatic heterocyclic group, and their use in therapeutics 21 1982
 
DEPARTMENT OF VETERANS AFFAIRS (1)
6,559,167 Prodrugs of proton pump inhibitors 19 2001
 
EISAI R&D MANAGEMENT CO., LTD. (1)
6,841,549 Condensed imidazole compounds and a therapeutic agent for diabetes mellitus 14 2001
 
ELI LILLY AND COMPANY (1)
2004/0122,001 Pharmaceutical compounds 8 2004
 
G. D. SEARLE & CO. (1)
5,716,964 Tetrazolyl substituted imidazo?1,2-a!pyridinylalkyl compounds for treatment of neurotoxic injury 9 1995
 
HITACHI, LTD. (1)
6,413,475 Automatic analysis apparatus with liquid level detection function 17 1998
 
JAPAN TOBACCO INC. (1)
2004/0082,635 Fused cyclic compounds and medicinal use thereof 38 2003
 
KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (1)
6,723,724 Isoxazolylalkylpiperazine derivatives having selective biological activity at dopamine D3 or D4 receptor, and preparation thereof 7 2001
 
LES LABORATOIRES SERVIER (1)
6,696,469 Cyclobutenedione compounds 7 2001
 
MERCK & CO., INC. (1)
5,057,517 Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents 31 1989
 
NOVARTIS AG (1)
2003/0028,018 Quinolinone derivatives 32 2002
 
PETER MACCALLUM CANCER INSTITUTE (1)
6,548,505 Radioprotectors 13 2000
 
PFIZER INC. (1)
5,338,740 Angiotensin II receptor antagonists 29 1993
 
ROCHE DIAGNOSTICS OPERATIONS, INC. (1)
2002/0072,053 Immunoassay based on DNA replication using labeled primer 7 2000
 
SANDOZ LTD. (1)
4,652,565 Piperazine derivatives, their production and pharmaceutical compositions containing them 2 1985
 
TAIJI BIOMEDICAL, INC. (1)
2002/0147,197 Methods and compositions for enhancing pharmaceutical treatments 24 2002
 
THE UPJOHN COMPANY (1)
5,502,187 Pharmaceutically active bicyclic-heterocyclic amines 67 1994
 
UDC IRELAND LIMITED (1)
6,620,529 Materials for light emitting devices and light emitting devices using the same 11 2000
 
XEROX CORPORATION (1)
6,376,141 Photoreceptor with layered charge generation section 22 2001
 
OTHER [CHECK PATENT PROFILE FOR ASSIGNMENT INFORMATION] (3)
6,409,237 Authorized-user, tag separable, tamper-evident seal with fixed-in-place, reusable catches for thin-walled containers 13 2001
2003/0069,248 Quinazoline derivatives as medicaments 37 2001
2003/0220,365 Cell adhesion-inhibiting antiinflammatory compounds 29 2003

Patent Citation Ranking

Forward Cites

  • No Forward Cites to Display

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Mar 1, 2013
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 1, 2017
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 1, 2021
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00